Document is current
Any future updates will be listed below
-
Authors
Singh, Jasvinder A. http://orcid.org/0000-0003-3485-0006
-
Funding
Funding for this research was provided by:
research funds from the division of rheumatology at the university of alabama at birmingham (No number)
the resources and use of facilities at the birmingham va medical center, birmingham, alabama, usa (No number)
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 9 November 2021
First Online: 1 December 2021
Declarations
:
: The University of Alabama at Birmingham’s Institutional Review Board approved this study (X120404005), and all investigations were conducted in conformity with the ethical principles of research.
: No individual person’s data were presented in any form in this study, and therefore, no consent to publish is required.
: JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point Communications, and the National Institutes of Health and the American College of Rheumatology. JAS has received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Electronics North America. JAS owns stock options in TPT Global Tech, Vaxart Pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics Tonix Pharmaceuticals Holding Corp., and Charlotte’s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals. JAS is on the Speaker’s Bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 8 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees; the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and the co-chair of the ACR Criteria and Response Criteria Subcommittee.
